MDWD
MediWound Ltd.
Biotechnology
Market Cap$222M
5Y Perf.+20.3%
Compare Stocks
4 / 10Try these comparisons:
Stock Comparison
MDWD vs HALO vs ARWR vs ALNY
Revenue, margins, valuation, and 5-year total return — side by side.
HALO
Halozyme Therapeutics, Inc.
Biotechnology
Market Cap$7.68B
5Y Perf.+168.6%
ARWR
Arrowhead Pharmaceuticals, Inc.
Biotechnology
Market Cap$10.92B
5Y Perf.+141.8%
ALNY
Alnylam Pharmaceuticals, Inc.
Biotechnology
Market Cap$39.48B
5Y Perf.+118.8%
MDWD vs HALO vs ARWR vs ALNY — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | MDWD | HALO | ARWR | ALNY |
|---|---|---|---|---|
| Industry | Biotechnology | Biotechnology | Biotechnology | Biotechnology |
| Market Cap | $222M | $7.68B | $10.92B | $39.48B |
| Revenue (TTM) | $17M | $1.40B | $622M | $4.29B |
| Net Income (TTM) | $-24M | $317M | $-301M | $577M |
| Gross Margin | 19.2% | 81.9% | 85.1% | 80.9% |
| Operating Margin | -149.1% | 58.4% | -35.7% | 17.5% |
| Forward P/E | — | 8.1x | — | 44.2x |
| Total Debt | $9M | $0.00 | $366M | $1.28B |
| Cash & Equiv. | $5M | $134M | $227M | $1.66B |
MDWD vs HALO vs ARWR vs ALNY — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
MDWD
HALO
ARWR
ALNY
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| MediWound Ltd. (MDWD) | 100 | 120.3 | +20.3% |
| Halozyme Therapeuti… (HALO) | 100 | 268.6 | +168.6% |
| Arrowhead Pharmaceu… (ARWR) | 100 | 241.8 | +141.8% |
| Alnylam Pharmaceuti… (ALNY) | 100 | 218.8 | +118.8% |
Price return only. Dividends and distributions are not included.
Quick Verdict: MDWD vs HALO vs ARWR vs ALNY
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: HALO leads in 4 of 7 categories, making it the strongest pick for valuation and capital efficiency and profitability and margin quality. Arrowhead Pharmaceuticals, Inc. is the stronger pick specifically for growth and revenue expansion and recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
MDWD
MediWound Ltd.
The Specific-Use Pick
MDWD plays a supporting role in this comparison — it may shine differently against other peers.
Best for: healthcare exposure
HALO
Halozyme Therapeutics, Inc.
The Income Pick
HALO carries the broadest edge in this set and is the clearest fit for income & stability and sleep-well-at-night.
- beta 0.56
- Lower volatility, beta 0.56, current ratio 4.66x
- Beta 0.56, current ratio 4.66x
- Lower P/E (8.1x vs 44.2x)
Best for: income & stability and sleep-well-at-night
ARWR
Arrowhead Pharmaceuticals, Inc.
The Growth Play
ARWR is the #2 pick in this set and the best alternative if growth exposure and long-term compounding is your priority.
- Rev growth 232.6%, EPS growth 99.8%, 3Y rev CAGR 50.5%
- 12.5% 10Y total return vs HALO's 5.7%
- 232.6% revenue growth vs MDWD's -16.1%
- +496.9% vs HALO's -7.1%
Best for: growth exposure and long-term compounding
ALNY
Alnylam Pharmaceuticals, Inc.
The Lower-Volatility Pick
ALNY lags the leaders in this set but could rank higher in a more targeted comparison.
Best for: healthcare exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | ARWR | 232.6% revenue growth vs MDWD's -16.1% |
| Value | HALO | Lower P/E (8.1x vs 44.2x) |
| Quality / Margins | HALO | 22.7% margin vs MDWD's -140.8% |
| Stability / Safety | HALO | Beta 0.56 vs ARWR's 1.81 |
| Dividends | Tie | None of these 4 stocks pay a meaningful dividend |
| Momentum (1Y) | ARWR | +496.9% vs HALO's -7.1% |
| Efficiency (ROA) | HALO | 12.5% ROA vs MDWD's -30.2%, ROIC 73.4% vs -49.5% |
MDWD vs HALO vs ARWR vs ALNY — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2025
Segment breakdown not available.
FY 2025
MDWD vs HALO vs ARWR vs ALNY — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLHALOLAGGINGALNY
Who Leads Where
HALO leads in 3 of 6 categories
ARWR leads 1 • MDWD leads 0 • ALNY leads 0 • 1 tied
Explore the data ↓ALNYAlnylam Pharmaceutica…
0leads
MDWDMediWound Ltd.
0leads
ARWRArrowhead Pharmaceuti…
1leads
HALOHalozyme Therapeutics…
3leads
6 Total Categories
CATEGORYLEADERvs ARWRvs MDWDMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
HALO3/6
Valuation MetricsMultiples, price ratios, and targets
HALO4/6
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
HALO6/9
Total Returns1Y, 3Y, 5Y total returns with dividends
ARWR3/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
HALO leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
ALNY is the larger business by revenue, generating $4.3B annually — 252.8x MDWD's $17M. HALO is the more profitable business, keeping 22.7% of every revenue dollar as net income compared to MDWD's -140.8%. On growth, ALNY holds the edge at +96.4% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | MDWDMediWound Ltd. | HALOHalozyme Therapeu… | ARWRArrowhead Pharmac… | ALNYAlnylam Pharmaceu… |
|---|---|---|---|---|
| RevenueTrailing 12 months | $17M | $1.4B | $622M | $4.3B |
| EBITDAEarnings before interest/tax | -$23M | $945M | -$203M | $677M |
| Net IncomeAfter-tax profit | -$24M | $317M | -$301M | $577M |
| Free Cash FlowCash after capex | -$21M | $645M | -$51M | $641M |
| Gross MarginGross profit ÷ Revenue | +19.2% | +81.9% | +85.1% | +80.9% |
| Operating MarginEBIT ÷ Revenue | -149.1% | +58.4% | -35.7% | +17.5% |
| Net MarginNet income ÷ Revenue | -140.8% | +22.7% | -48.4% | +13.5% |
| FCF MarginFCF ÷ Revenue | -122.7% | +46.2% | -8.2% | +15.0% |
| Rev. Growth (YoY)Latest quarter vs prior year | -68.0% | +51.6% | -86.4% | +96.4% |
| EPS Growth (YoY)Latest quarter vs prior year | -55.6% | -2.1% | -133.8% | +4.4% |
HALO leads this category, winning 3 of 6 comparable metrics.
Valuation Metrics
HALO leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
At 25.5x trailing earnings, HALO trades at a 80% valuation discount to ALNY's 127.0x P/E. On an enterprise value basis, HALO's 8.3x EV/EBITDA is more attractive than ARWR's 90.4x.
| Metric | MDWDMediWound Ltd. | HALOHalozyme Therapeu… | ARWRArrowhead Pharmac… | ALNYAlnylam Pharmaceu… |
|---|---|---|---|---|
| Market CapShares × price | $222M | $7.7B | $10.9B | $39.5B |
| Enterprise ValueMkt cap + debt − cash | $226M | $7.5B | $11.1B | $39.1B |
| Trailing P/EPrice ÷ TTM EPS | -8.22x | 25.46x | -6389.34x | 127.00x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 8.09x | — | 44.18x |
| PEG RatioP/E ÷ EPS growth rate | — | 1.11x | — | — |
| EV / EBITDAEnterprise value multiple | — | 8.34x | 90.41x | 70.17x |
| Price / SalesMarket cap ÷ Revenue | 13.07x | 5.50x | 13.16x | 10.63x |
| Price / BookPrice ÷ Book value/share | 4.50x | 165.47x | 20.71x | 50.50x |
| Price / FCFMarket cap ÷ FCF | — | 11.91x | 69.58x | 84.84x |
HALO leads this category, winning 4 of 6 comparable metrics.
Profitability & Efficiency
HALO leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
HALO delivers a 6.5% return on equity — every $100 of shareholder capital generates $6 in annual profit, vs $-66 for MDWD. MDWD carries lower financial leverage with a 0.20x debt-to-equity ratio, signaling a more conservative balance sheet compared to ALNY's 1.62x. On the Piotroski fundamental quality scale (0–9), ARWR scores 6/9 vs MDWD's 4/9, reflecting solid financial health.
| Metric | MDWDMediWound Ltd. | HALOHalozyme Therapeu… | ARWRArrowhead Pharmac… | ALNYAlnylam Pharmaceu… |
|---|---|---|---|---|
| ROE (TTM)Return on equity | -65.8% | +6.5% | -55.5% | +98.3% |
| ROA (TTM)Return on assets | -30.2% | +12.5% | -18.1% | +11.8% |
| ROICReturn on invested capital | -49.5% | +73.4% | +9.3% | +33.4% |
| ROCEReturn on capital employed | -47.0% | +38.2% | +8.8% | +15.3% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 5 | 6 | 6 |
| Debt / EquityFinancial leverage | 0.20x | — | 0.73x | 1.62x |
| Net DebtTotal debt minus cash | $4M | -$134M | $140M | -$379M |
| Cash & Equiv.Liquid assets | $5M | $134M | $227M | $1.7B |
| Total DebtShort + long-term debt | $9M | $0 | $366M | $1.3B |
| Interest CoverageEBIT ÷ Interest expense | -2.05x | 46.08x | -1.03x | 2.02x |
HALO leads this category, winning 6 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
ARWR leads this category, winning 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ALNY five years ago would be worth $22,537 today (with dividends reinvested), compared to $5,519 for MDWD. Over the past 12 months, ARWR leads with a +496.9% total return vs HALO's -7.1%. The 3-year compound annual growth rate (CAGR) favors HALO at 29.1% vs ALNY's 12.1% — a key indicator of consistent wealth creation.
| Metric | MDWDMediWound Ltd. | HALOHalozyme Therapeu… | ARWRArrowhead Pharmac… | ALNYAlnylam Pharmaceu… |
|---|---|---|---|---|
| YTD ReturnYear-to-date | -6.2% | -7.3% | +15.0% | -26.1% |
| 1-Year ReturnPast 12 months | -3.3% | -7.1% | +496.9% | +7.0% |
| 3-Year ReturnCumulative with dividends | +62.9% | +115.3% | +92.7% | +40.9% |
| 5-Year ReturnCumulative with dividends | -44.8% | +37.0% | +17.4% | +125.4% |
| 10-Year ReturnCumulative with dividends | -68.4% | +570.7% | +1253.3% | +411.9% |
| CAGR (3Y)Annualised 3-year return | +17.7% | +29.1% | +24.4% | +12.1% |
ARWR leads this category, winning 3 of 6 comparable metrics.
Risk & Volatility
Evenly matched — HALO and ARWR each lead in 1 of 2 comparable metrics.
Risk & Volatility
HALO is the less volatile stock with a 0.56 beta — it tends to amplify market swings less than ARWR's 1.81 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ARWR currently trades 98.1% from its 52-week high vs ALNY's 59.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | MDWDMediWound Ltd. | HALOHalozyme Therapeu… | ARWRArrowhead Pharmac… | ALNYAlnylam Pharmaceu… |
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.13x | 0.56x | 1.81x | 0.71x |
| 52-Week HighHighest price in past year | $22.51 | $82.22 | $79.48 | $495.55 |
| 52-Week LowLowest price in past year | $14.90 | $47.50 | $12.44 | $245.96 |
| % of 52W HighCurrent price vs 52-week peak | +76.7% | +79.3% | +98.1% | +59.7% |
| RSI (14)Momentum oscillator 0–100 | 55.2 | 52.4 | 69.7 | 43.8 |
| Avg Volume (50D)Average daily shares traded | 83K | 1.4M | 1.9M | 1.1M |
Evenly matched — HALO and ARWR each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: MDWD as "Buy", HALO as "Buy", ARWR as "Buy", ALNY as "Buy". Consensus price targets imply 108.5% upside for MDWD (target: $36) vs 4.2% for ARWR (target: $81).
| Metric | MDWDMediWound Ltd. | HALOHalozyme Therapeu… | ARWRArrowhead Pharmac… | ALNYAlnylam Pharmaceu… |
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $36.00 | $78.33 | $81.22 | $445.67 |
| # AnalystsCovering analysts | 13 | 27 | 20 | 52 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — |
| Dividend StreakConsecutive years of raises | — | — | — | — |
| Dividend / ShareAnnual DPS | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +4.5% | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
HALO leads in 3 of 6 categories (Income & Cash Flow, Valuation Metrics). ARWR leads in 1 (Total Returns). 1 tied.
Best OverallHalozyme Therapeutics, Inc. (HALO)Leads 3 of 6 categories
Loading custom metrics...
MDWD vs HALO vs ARWR vs ALNY: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is MDWD or HALO or ARWR or ALNY a better buy right now?
For growth investors, Arrowhead Pharmaceuticals, Inc.
(ARWR) is the stronger pick with 232. 6% revenue growth year-over-year, versus -16. 1% for MediWound Ltd. (MDWD). Halozyme Therapeutics, Inc. (HALO) offers the better valuation at 25. 5x trailing P/E (8. 1x forward), making it the more compelling value choice. Analysts rate MediWound Ltd. (MDWD) a "Buy" — based on 13 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — MDWD or HALO or ARWR or ALNY?
On trailing P/E, Halozyme Therapeutics, Inc.
(HALO) is the cheapest at 25. 5x versus Alnylam Pharmaceuticals, Inc. at 127. 0x. On forward P/E, Halozyme Therapeutics, Inc. is actually cheaper at 8. 1x.
03Which is the better long-term investment — MDWD or HALO or ARWR or ALNY?
Over the past 5 years, Alnylam Pharmaceuticals, Inc.
(ALNY) delivered a total return of +125. 4%, compared to -44. 8% for MediWound Ltd. (MDWD). Over 10 years, the gap is even starker: ARWR returned +1253% versus MDWD's -68. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — MDWD or HALO or ARWR or ALNY?
By beta (market sensitivity over 5 years), Halozyme Therapeutics, Inc.
(HALO) is the lower-risk stock at 0. 56β versus Arrowhead Pharmaceuticals, Inc. 's 1. 81β — meaning ARWR is approximately 225% more volatile than HALO relative to the S&P 500. On balance sheet safety, MediWound Ltd. (MDWD) carries a lower debt/equity ratio of 20% versus 162% for Alnylam Pharmaceuticals, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — MDWD or HALO or ARWR or ALNY?
By revenue growth (latest reported year), Arrowhead Pharmaceuticals, Inc.
(ARWR) is pulling ahead at 232. 6% versus -16. 1% for MediWound Ltd. (MDWD). On earnings-per-share growth, the picture is similar: Alnylam Pharmaceuticals, Inc. grew EPS 206. 9% year-over-year, compared to -25. 4% for Halozyme Therapeutics, Inc.. Over a 3-year CAGR, ALNY leads at 53. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — MDWD or HALO or ARWR or ALNY?
Halozyme Therapeutics, Inc.
(HALO) is the more profitable company, earning 22. 7% net margin versus -140. 8% for MediWound Ltd. — meaning it keeps 22. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HALO leads at 58. 4% versus -149. 1% for MDWD. At the gross margin level — before operating expenses — ARWR leads at 97. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is MDWD or HALO or ARWR or ALNY more undervalued right now?
On forward earnings alone, Halozyme Therapeutics, Inc.
(HALO) trades at 8. 1x forward P/E versus 44. 2x for Alnylam Pharmaceuticals, Inc. — 36. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for MDWD: 108. 5% to $36. 00.
08Which pays a better dividend — MDWD or HALO or ARWR or ALNY?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
09Is MDWD or HALO or ARWR or ALNY better for a retirement portfolio?
For long-horizon retirement investors, Halozyme Therapeutics, Inc.
(HALO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 56), +570. 7% 10Y return). Both have compounded well over 10 years (HALO: +570. 7%, MDWD: -68. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between MDWD and HALO and ARWR and ALNY?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: MDWD is a small-cap quality compounder stock; HALO is a small-cap high-growth stock; ARWR is a mid-cap high-growth stock; ALNY is a mid-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
Revenue Growth>
%
(MDWD: -68.0% · HALO: 51.6%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.